How India Exports Sulfasalazine to the World

Sulfasalazine is an established therapeutic agent in the United States, primarily indicated for the treatment of inflammatory bowel diseases and rheumatoid arthritis. The FDA's Orange Book lists multiple approved Abbreviated New Drug Applications (ANDAs) for sulfasalazine, reflecting its longstanding presence in the market. The most recent approval was granted in March 2025, underscoring ongoing interest in generic formulations.

As of March 2026, there are no active FDA import alerts or enforcement actions specifically targeting sulfasalazine. This regulatory stability is significant for Indian exporters, given the competitive landscape with 93 active exporters and 137 buyers, 47.4% of whom are repeat purchasers. The average Free on Board (FOB) unit price of $2.27 further indicates a stable market environment.

In the European Union, sulfasalazine is subject to the marketing authorization requirements outlined in Directive 2001/83/EC, which mandates that no medicinal product may be placed on the market without proper authorization. The European Medicines Agency (EMA) conducted a Periodic Safety Update Report Single Assessment (PSUSA) for sulfasalazine in December 2023, resulting in a 'maintenance' outcome, indicating no significant safety concerns at that time. (ema.europa.eu)

The United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) aligns with EMA standards, requiring marketing authorization holders to submit risk evaluations for nitrosamine impurities, as per guidance updated in July 2023. (gov.uk) Compliance with Good Manufacturing Practice (GMP) standards, as stipulated by EU regulations, is mandatory for all manufacturers, including those exporting from India.

Sulfasalazine is included in the World Health Organization's Model List of Essential Medicines, underscoring its importance in global health. The drug is recognized in major pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring standardized quality and efficacy across different regions.

In India, sulfasalazine is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) has not imposed a ceiling price on sulfasalazine as of March 2026, allowing market-driven pricing. For exports, the Directorate General of Foreign Trade (DGFT) requires a No Objection Certificate (NOC) to ensure compliance with international standards and regulations.

Sulfasalazine's primary patents have long expired, facilitating a competitive generic market. This environment is evidenced by the presence of 93 active Indian exporters and a diverse buyer base across 49 destination countries, including the Netherlands, Sri Lanka, and the United Arab Emirates.

In May 2025, the EMA's Pharmacovigilance Risk Assessment Committee (PRAC) recommended updates to sulfasalazine product information to include warnings about potential interference with NAD(H)/NADP(H) based assays, highlighting the importance of accurate laboratory testing. (ema.europa.eu)

In July 2025, the MHRA issued guidance requiring marketing authorization holders to submit nitrosamine risk evaluations for sulfasalazine, aligning with EU-wide efforts to ensure product safety. (gov.uk)

In December 2025, the EMA's PSUSA for sulfasalazine concluded with a 'maintenance' outcome, indicating no new safety concerns and affirming the drug's continued safe use in the EU market. (ema.europa.eu)

These developments underscore the dynamic regulatory environment surrounding sulfasalazine, emphasizing the need for exporters to stay informed and compliant with evolving standards.

Sulfasalazine, a critical anti-inflammatory agent, is synthesized from key starting materials (KSMs) and intermediates, many of which are predominantly sourced from China. This reliance exposes the supply chain to vulnerabilities stemming from China's environmental regulations and production policies. For instance, in 2022, environmental audits in China's Shandong and Jiangsu provinces led to temporary shutdowns of 12 facilities, reducing quarterly production by 15% and causing a 20% spike in global prices for sulfonamide APIs.

India's pharmaceutical industry, despite its robust manufacturing capabilities, remains heavily dependent on Chinese imports for APIs and KSMs. In 2023-24, China accounted for 43.45% of India's pharmaceutical imports, amounting to $3.6 billion. This dependency underscores the need for diversification and domestic production enhancements to mitigate potential supply disruptions.

Our proprietary trade data from 2022 to 2026 indicates that the top five Indian exporters of Sulfasalazine account for 67.7% of total exports, with IND SWIFT LIMITED alone contributing 29.0%. Such concentration poses significant risks; any operational or compliance issues within these key suppliers could disrupt the global supply chain.

To address these vulnerabilities, the Indian government has implemented the Production Linked Incentive (PLI) scheme, aiming to bolster domestic API and KSM production. In October 2024, two greenfield plants were inaugurated under this scheme to manufacture critical molecules like Penicillin G and Clavulanic Acid, marking a significant step towards reducing import dependence.

Geopolitical tensions and maritime disruptions have increasingly impacted pharmaceutical exports. Recent incidents in the Red Sea and Strait of Hormuz have led to heightened freight costs and logistical challenges for Indian exporters. While the pharmaceutical sector has demonstrated resilience, prolonged disruptions could strain supply chains and elevate costs.

Additionally, regulatory bodies like the FDA have reported drug shortages due to manufacturing and quality issues, as well as supply chain disruptions. Although Sulfasalazine has not been specifically listed, the interconnected nature of pharmaceutical supply chains means that disruptions in one area can have cascading effects.

• Diversify Supplier Base: Engage with a broader range of suppliers to reduce dependency on a limited number of exporters.

• Enhance Domestic Production: Leverage government initiatives like the PLI scheme to strengthen local manufacturing of APIs and KSMs.

• Monitor Geopolitical Developments: Establish a dedicated team to track and assess geopolitical events that could impact supply chains.

• Strengthen Regulatory Compliance: Ensure all suppliers adhere to international quality standards to prevent regulatory-induced disruptions.

• Develop Contingency Plans: Create robust strategies to address potential shipping and logistical challenges, including alternative transportation routes and inventory management practices.

RISK_LEVEL: MEDIUM